VativoRx, LLC

07/21/2025

We’re live at the Health Care Administrators Association® (HCAA) TPA Summit in Dallas, and we’re helping TPAs turn overlooked J-code claims into real rebate revenue.

✅ Reclaim value from existing claims
✅ Strengthen client & broker relationships
✅ Offset admin costs with no disruption

Stop by Booth #5 to meet Jim Haidet and Bruce Marwil and learn how our tech-enabled, HIPAA-compliant platform makes rebate capture seamless and impactful.

Let’s rethink your rebate strategy, together.



https://www.linkedin.com/feed/update/urn:li:activity:7353061871416922112

07/18/2025

💡 New: The 2025 rebate gap you may not see — but are definitely paying for.

Most healthcare payers lean on rebates to offset drug costs, but according to PSG’s latest trends report, there’s one major flaw in how they’re doing it: lack of coordination between pharmacy and medical benefit rebates.

This edition of The Rebate Report unpacks:
• What the data says about shifting drug cost pressures
• Why medical rebate eligibility often gets overlooked
• How forward-looking plans are adapting their rebate approach

🔍 Plus, how to tell if your organization is leaving money on the table.

👇 Read the newsletter & share your take — are your rebates truly working together?

https://www.linkedin.com/pulse/rebates-dont-work-silos-vativorx-llc-imgee

07/16/2025

📢 FDA approves Moderna’s next-gen COVID vax mNEXSPIKE® for adults 65+ & high-risk 12–64 y/o. Offers longer shelf life & easier storage vs Spikevax®. Stronger immune response & fewer side effects seen in trials. Launch expected for 2025-26 season.

👉 https://vativorx.com/pharmacy-bulletin-07-16-2025/

On May 31, 2025, the US Food and Drug Administration (FDA) approved Moderna’s mNEXSPIKE® (COVID-19 vaccine, mRNA-1283) for use in all adults 65 years and older, and individuals between 12 years and 64 years of age with at least one or more underlying conditions that puts them at risk for severe o...

07/10/2025

Most TPAs aren’t capturing rebates tied to physician-administered drugs — and that’s lost value for clients.

VativoRx helps unlock a high-impact savings channel hidden in your current claims. No new systems, no disruption.

Catch us at Booth #5 at in Dallas, July 21–23!

07/08/2025

Big savings, simple ex*****on. VativoRx + Vativis are teaming up at to show TPAs how to unlock untapped value for clients. See you at Booth #5!

07/08/2025

🚨 FDA approves Yutrepia™ (treprostinil) for PAH & PH-ILD. Dry powder inhaler uses PRINT™ tech for easier, deeper lung delivery. Liquidia expects launch in 2 weeks, priced at ~$24K/28 days.

Read more: https://vativorx.com/pharmacy-bulletin-07-08-2025/

On May 23, 2025, the US Food and Drug Administration (FDA) granted approval to Yutrepia™ (treprostinil – Liquidia) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise abilit...

07/02/2025

You might be earning rebates today… but could you defend them tomorrow?

In Edition 9 of The Rebate Report, we explore what it takes to be audit-ready in today’s evolving rebate landscape.

Whether you're a provider, health plan, or TPA—if you're capturing rebate dollars, you need a defensible process behind them.

💬 Have you faced a rebate audit yet? We’d love to hear your experience.

👉 https://www.linkedin.com/pulse/preparing-rebate-audit-lessons-from-field-vativorx-llc-lyeze/

Rebate audits aren’t just coming—they’re already happening. As manufacturers tighten data validation requirements and oversight increases across both medical and pharmacy channels, organizations need to be ready to defend every claim.

07/02/2025

🚨 FDA approves Yutrepia™ (treprostinil) inhalation powder for PAH & PH-ILD. Uses low-effort device for deep-lung delivery. Launch expected soon.

https://vativorx.com/pharmacy-bulletin-07-02-2025/

On May 23, 2025, the US Food and Drug Administration (FDA) granted approval to Yutrepia™ (treprostinil – Liquidia) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise abilit...

06/26/2025

🔄 FDA expands Jivi® approval to include kids 7+ with hemophilia A. Now approved for on-demand use, surgery & prophylaxis.

https://vativorx.com/pharmacy-bulletin-06-26-2025/

On May 16, 2025, the US Food and Drug Administration (FDA) granted Novavax’s Nuvavoxid™ [coronavirus disease 2019 (COVID-19) vaccine, adjuvanted] full approval for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years an...

06/24/2025

🆕 Generics to Promacta® launched: Eltrombopag olamine tabs (Hetero Labs) & oral suspension (Annora Pharma) now available via Camber. Treats thrombocytopenia & aplastic anemia.

https://vativorx.com/pharmacy-bulletin-06-24-2025/

The US Food and Drug Administration (FDA) approved Hetero Lab’s eltrombopag olamine tablets on Jan. 17, 2025, and Annora Pharma’s eltrombopag olamine oral suspension on April 18, 2024, reference to Novartis’ Promacta. Promacta, a thrombopoietin receptor, treats thrombocytopenia and severe a...

06/23/2025

🆕 Multiple Stelara® biosimilars—incl. Selarsdi™ & Wezlana™—now have FDA interchangeable status as of April 30, 2025. Pharmacies can substitute without a prescriber OK (state laws apply).

https://vativorx.com/pharmacy-bulletin-06-23-2025/

Effective April 30, 2025, Alvotech and Teva announced that previously US Food and Drug Administration (FDA) approved Selarsdi™ (ustekinumab-aekn) is now interchangeable with reference biologic Stelara (ustekinumab - Genentech).

06/18/2025

🧠 FDA approves Rinvoq® for giant cell arteritis (GCA), expanding its autoimmune reach. 46.4% achieved remission at 52 weeks.

https://vativorx.com/pharmacy-bulletin-06-18-2025/

On April 29, 2025, the US Food and Drug Administration (FDA) approved AbbVie’s Rinvoq® (upadacitinib) for the treatment of adults with giant cell arteritis (GCA). Sometimes called temporal arteritis because it mainly affects arteries in the head and neck, GCA is an autoimmune disease that involve...